The authors of a recent Lancet report argue that obesity should not just be seen as a risk factor for other diseases — but in some cases, should be seen as a disease itself. The position could change ...

Weight loss jabs could "herald a whole new era of preventative cancer medicine" by slashing risk of obesity-related tumours, experts have said. Research presented at the European Congress on Obesity ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide, which ...

Semaglutide effectively treats liver disease ... The placebo-controlled outcome trial of participants with a life-threatening form of liver disease known as Metabolic dysfunction associated ...

Some pharmacies also produce compounded semaglutide for people who need something different from what’s commercially available — whether that means a custom dose, an alternative form ...

She will still sell the commercial products, like Ozempic and Wegovy, and will continue selling an oral form of the semaglutide. This is allowed because it's not available commercially.

In 81.7% of visits, semaglutide was the only medication implicated and was almost always in injectable form (94.0%); medication errors were involved in 9.0% of visits. "Clinicians could counsel ...

Get Instant Summarized Text (Gist) Oral semaglutide, a glucagon-like peptide-1 receptor agonist, significantly reduces cardiovascular events in individuals with type 2 diabetes, atherosclerotic ...

A new clinical trial led by researchers at the University of North Carolina School of Medicine has revealed that the oral form of semaglutide (GLP-1) significantly reduces the risk of heart ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...